Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...

Analysts expected earnings of $1.61 per share on $15.48 billion in revenue. Shares of Merck & Co. Inc. tumbled nearly 10%, or $9.64, to $90.15 at the opening bell Tuesday.

Witnesses Sought In Crash Killing MD Twin, 20, As Suspect Flees Scene: PA State Police Pennsylvania State Police ... The crash happened on the Susquehanna Trail South in Springfield Township, York ...

The crash happened on the Susquehanna Trail South in Springfield Township, York County, on Friday, Jan. 17, at 9:12 p.m., as Daily Voice previously reported. McEvoy was the front-seat passenger in a ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

2025 EPS Guidance: $8.88 to $9.03. Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...